PILA PHARMA AB (5KC) AI Stock Analysis

0 Followers

PILA PHARMA AB

(Frankfurt:5KC)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused drug-development strategyA focused development strategy can concentrate scarce resources and scientific effort on a large, clearly defined disease area. PILA’s emphasis on type 2 diabetes and a single lead program may support coherent execution and create meaningful value if clinical development succeeds.

Negative Factors

Severe revenue deteriorationSharp revenue deterioration leaves PILA with limited demonstrated commercial traction and weak operating leverage. Because the company is pre-commercial, continued low or falling revenue increases dependence on successful clinical progress and makes it harder to fund development through internally generated business.

PILA PHARMA AB (5KC) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 6.87M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -4.1
Beta (1Y): 0.18
Revenue Growth: -70.92%
EPS Growth: -27.35%
Country: Germany
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

PILA PHARMA AB Business Overview & Revenue Model

Company Description

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating...

PILA PHARMA AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:5KC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:ONCOZ	39Underperform	SEK 89.57M	-1.38	-970.69%	―	115.26%	-230.43%
SE:ACE	38Underperform	SEK 77.45M	-1.34	-62.23%	―	―	50.59%
SE:MODTX	30Underperform	SEK 29.16M	-0.95	-177.45%	―	―	0.22%

* Healthcare Sector Average

Performance Comparison

DE:5KC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:5KC	PILA PHARMA AB	0.14	-0.06	-30.92%
SE:ONCOZ	OncoZenge AB	3.25	-1.68	-34.07%
SE:ACE	Ascelia Pharma AB	0.58	-2.29	-79.76%
SE:MODTX	Modus Therapeutics Holding AB	0.17	-0.21	-54.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

PILA PHARMA AB AI Stock Analysis